Sartorius AG
XETRA:SRT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
168
288
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sartorius AG
Sartorius AG
Total Equity
Sartorius AG
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sartorius AG
XETRA:SRT
|
Total Equity
€2.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
26%
|
CAGR 10-Years
21%
|
|
|
Carl Zeiss Meditec AG
XETRA:AFX
|
Total Equity
€2.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Stratec SE
XETRA:SBS
|
Total Equity
€227.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
Total Equity
€248.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Siemens Healthineers AG
XETRA:SHL
|
Total Equity
€18.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Draegerwerk AG & Co KGaA
XETRA:DRW8
|
Total Equity
€1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
Sartorius AG
Glance View
Sartorius AG is a globally recognized leader in the biopharmaceutical and laboratory equipment sectors, dedicated to enhancing the efficiency of research and production processes. Founded in 1870 and headquartered in Göttingen, Germany, this innovative company provides a comprehensive range of products and services that support the life sciences industry—from advanced laboratory instruments to high-quality access materials for biopharmaceutical manufacturing. As the demand for biotechnological solutions continues to rise, particularly in response to global health challenges, Sartorius stands out by offering critical tools and technologies, positioning itself at the forefront of a thriving market with sustainable growth potential. Investors will find Sartorius particularly attractive due to its robust business model, marked by significant investments in research and development that fuel continuous innovation. The company has experienced impressive revenue growth, bolstered by strategic acquisitions that expand its technological capabilities and market reach. With a committed focus on sustainability and efficiency, Sartorius not only drives profitability but also aligns with the growing investor preference for socially responsible enterprises. As healthcare demands increase and the biopharmaceutical industry evolves, Sartorius AG offers a compelling investment opportunity characterized by a strong market position, strategic foresight, and a commitment to improving human health across the globe.
See Also
What is Sartorius AG's Total Equity?
Total Equity
2.7B
EUR
Based on the financial report for Sep 30, 2024, Sartorius AG's Total Equity amounts to 2.7B EUR.
What is Sartorius AG's Total Equity growth rate?
Total Equity CAGR 10Y
21%
Over the last year, the Total Equity growth was 29%. The average annual Total Equity growth rates for Sartorius AG have been 29% over the past three years , 26% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
